Analysts Set Astrana Health, Inc. (NASDAQ:ASTH) PT at $62.00

Astrana Health, Inc. (NASDAQ:ASTH) has earned an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $62.00.

A number of equities analysts have recently weighed in on ASTH shares. Stifel Nicolaus upped their price objective on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. TD Cowen assumed coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. Truist Financial boosted their target price on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. KeyCorp initiated coverage on shares of Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, BTIG Research raised their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd.

Institutional Trading of Astrana Health

Several institutional investors and hedge funds have recently modified their holdings of ASTH. GAMMA Investing LLC bought a new position in Astrana Health in the third quarter worth approximately $34,000. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health in the 3rd quarter worth $35,000. Central Pacific Bank Trust Division bought a new position in shares of Astrana Health during the 3rd quarter worth $160,000. Everence Capital Management Inc. purchased a new position in shares of Astrana Health during the third quarter valued at $272,000. Finally, Granite Bay Wealth Management LLC bought a new stake in shares of Astrana Health in the third quarter valued at about $290,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Shares of ASTH opened at $54.53 on Monday. The business has a 50-day simple moving average of $54.81 and a two-hundred day simple moving average of $46.91. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of 37.87, a PEG ratio of 2.05 and a beta of 1.24. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.62. Astrana Health has a 52 week low of $28.86 and a 52 week high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.01. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The company had revenue of $486.30 million during the quarter, compared to analyst estimates of $440.68 million. During the same period in the prior year, the firm posted $0.28 EPS. The firm’s quarterly revenue was up 39.7% compared to the same quarter last year. On average, analysts expect that Astrana Health will post 1.31 EPS for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.